A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.

Purpose: This is the first study to compare the pharmacokinetics of QL1101, a proposed bevacizumab biosimilar, with Avastin® sourced from Roche Diagnostics GmbH.Methods: In this double-blind, single-dose, parallel-group study, healthy male subjects were randomized 1:1 to receive QL1101 or Avastin® 3...

Descripción completa

Detalles Bibliográficos

Publicado en:	Cancer Chemotherapy & Pharmacology Vol. 85; no. 3; pp. 555 - 563
Autores principales:	Liu, Ya-nan, Huang, Jie, Guo, Can, Yang, Shuang, Ye, Ling, Wu, Shu-ting, Zhang, Xing-fei, Yang, Xiao-yan, Han, Cui-cui, Pei, Qi, Huang, Lu, He, Qing-nan, Yang, Guo-ping
Formato:	research Journal Article
Publicado:	Springer Nature Mar2020
Acceso en línea:	Ver este registro en EBSCOhost